ENCAPSULATION OF EXEMESTANE WITH β-CYCLODEXTRIN AND TERNARY AGENT: FORMULATION, EVALUATION AND ANTICANCER ACTIVITY
DOI:
https://doi.org/10.22159/ijap.2022v14i5.45129Keywords:
Exemesatne, β-cyclodextrin, Polymer, Organic acid, Complexation, Ternary complexAbstract
Objective: A potent aromatase inhibitor, Exemestane, is well known for its anticancer action in breast neoplasm. The vital problem of this medicament is its poor aqueous solubility, which hinders its dissolution in body fluids. Therefore, the present study targets to enhance the water solubility of Exemestane by means of its complexation with β-cyclodextrin and a suitable ternary agent.
Methods: Inclusion complexes of Exemestane with β-cyclodextrin and ternary agent were prepared by kneading and lyophilization technique. Different hydrophilic polymers and organic acids were screened for their influential ability as a co-complex with a carrier; β-cyclodextrin. The validation of complex formation was carried out by various solid-state techniques. The geometry of Exemestane in the β-cyclodextrin cavity was picturized in docking studies. The in vitro anticancer activity of prepared inclusion complex formulations carried out using MCF-7 cell lines
Results: Phase solubility analysis proved HPMC E5 as the best ternary agent for complexation of Exemestane with β-cyclodextrin as it improved the stability constant of the drug from 665.92 M-1 to 1238.38 M-1. The synthesized binary and ternary inclusion complexes exhibited 2.74 and 4.62 times enhanced solubilization of Exemestane. Likewise, the dissolution characteristics of Exemestane were improved, and drug release was increased by 1.18 and 1.42 times with binary and ternary freeze-dried formulations. Differential scanning calorimetry (DSC) and powder X-ray diffractometry (PXRD) study results presented the formation of binary and ternary complexes with significantly drooped crystallinity. Docking studies predicted encapsulation of rings A, B, and C of Exemestane in the cavity of β-cyclodextrin. In-line results were obtained in Fourier transform infrared (FTIR) studies. The cell growth inhibition of 62.78 % was achieved with a ternary complex of Exemestane which was far superior than the pure active moiety that showed mere 44.56 % of inhibition.
Conclusion: Altogether, it can be concluded that the inclusion complex of Exemestane boosted its aqueous solubility, resulting in its increased dissolution and in vitro anticancer activity in a breast cancer MCF-7 cell line.
Downloads
References
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi: 10.3322/caac.21708, PMID 35020204.
Preeti Tanaji Mane, Sangram Prakash Patil, Balaji Sopanrao Wakure, Pravin Shridhar Wakte. Breast cancer: understanding etiology, addressing molecular signaling pathways, identifying therapeutic targets and strategizing the treatment. IJRPS 2021;12(3):1757-69. doi: 10.26452/ijrps.v12i3.4779.
Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F. Clinical utility of exemestane in the treatment of breast cancer. Int J Womens Health. 2015;7:551-63. doi: 10.2147/IJWH.S69475. PMID 26064072.
Kaur S, Jena SK, Samal SK, Saini V, Sangamwar AT. Freeze-dried solid dispersion of exemestane: A way to negate an aqueous solubility and oral bioavailability problems. Eur J Pharm Sci. 2017;107:54-61. doi: 10.1016/j.ejps.2017.06.032, PMID 28663037.
Paul B, Sudandiradoss C. Aromatase inhibitors-types and advantages. Int J Pharm Pharm Sci. 2016;8(8):1-7.
Singh AK, Chaurasiya A, Awasthi A, Mishra G, Asati D, Khar RK. Oral bioavailability enhancement of exemestane from self-micro emulsifying drug delivery system (SMEDDS). AAPS PharmSciTech. 2009;10(3):906-16. doi: 10.1208/s12249-009-9281-7, PMID 19609837.
Jacob S, Nair AB. Cyclodextrin complexes: a perspective from drug delivery and formulation. Drug Dev Res. 2018;79(5):201-17. doi: 10.1002/ddr.21452, PMID 30188584.
Yavuz B, Bilensoy E, Vural I, Sumnu M. Alternative oral exemestane formulation: improved dissolution and permeation. Int J Pharm. 2010;398(1-2):137-45. doi: 10.1016/j.ijpharm.2010.07.046, PMID 20678561.
Gopinath S, Reddy CU, Chowdary KPR. Factorial studies on enhancement of dissolution rate and formulation of aceclofenac tablets employing βcd and kolliphor HS15. Int J Curr Pharm Res. 2015;7(1):43-6.
Aiassa V, Garnero C, Longhi MR, Zoppi A. Cyclodextrin multicomponent complexes: pharmaceutical applications. Pharmaceutics. 2021;13(7):1099. doi: 10.3390/ pharmaceutics 13071099, PMID 34371790.
Ding X, Zheng M, Lu J, Zhu X. Preparation and evaluation of binary and ternary inclusion complexes of fenofibrate/hydroxypropyl-β-cyclodextrin. J Incl Phenom Macrocycl Chem. 2018;91(1-2):17-24. doi: 10.1007/s10847-018-0793-1.
Miranda JCd, Martins TEA, Veiga F, Ferraz HG. Cyclodextrins and ternary complexes: technology to improve the solubility of poorly soluble drugs. Braz J Pharm Sci. 2011;47(4):665-81. doi: 10.1590/S1984-82502011000400003.
Chantasart D, Rakkaew P. Preparation and characterization of dry β-cyclodextrin-based ternary complexes of haloperidol and lactic acid for drug delivery. J Drug Deliv Sci Technol. 2019;52:73-82. doi: 10.1016/j.jddst.2019.04.011.
Taupitz T, Dressman JB, Buchanan CM, Klein S. Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole. Eur J Pharm Biopharm. 2013;83(3):378-87. doi: 10.1016/j.ejpb.2012.11.003. PMID 23201048.
Ghosh A, Biswas S, Ghosh T. Preparation and evaluation of silymarin β-cyclodextrin molecular inclusion complexes. J Young Pharm. 2011;3(3):205-10. doi: 10.4103/0975-1483.83759, PMID 21897659.
Alshehri S, Imam SS, Hussain A, Altamimi MA. Formulation of piperine ternary inclusion complex using β CD and HPMC: physicochemical characterization, molecular docking, and antimicrobial testing. Processes. 2020;8(11):1450. doi: 10.3390/pr8111450.
Vartak R, Patki M, Menon S, Jablonski J, Mediouni S, Fu Y. β-cyclodextrin polymer/Soluplus® encapsulated ebselen ternary complex (EβpolySol) as a potential therapy for vaginal candidiasis and pre-exposure prophylactic for HIV. Int J Pharm. 2020;589:119863. doi: 10.1016/j.ijpharm.2020.119863. PMID 32911046.
Huo ZJ, Wang SJ, Wang ZQ, Zuo WS, Liu P, Pang B. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: therapeutic efficacy evaluation. Cancer Sci. 2015;106(10):1429-37. doi: 10.1111/cas.12737, PMID 26177628.
Giri BR, Lee J, Lim DY, Kim DW. Docetaxel/dimethyl-β-cyclodextrin inclusion complexes: preparation, in vitro evaluation and physicochemical characterization. Drug Dev Ind Pharm. 2021;47(2):319-28. doi: 10.1080/ 03639045.2021.1879840, PMID 33576707.
Cirri M, Maestrelli F, Corti G, Furlanetto S, Mura P. Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization. J Pharm Biomed Anal. 2006;42(1):126-31. doi: 10.1016/ j.jpba.2005.11.029, PMID 16406448.
Jacob S, Nair AB. Cyclodextrin complexes: a perspective from drug delivery and formulation. Drug Dev Res. 2018;79(5):201-17. doi: 10.1002/ddr.21452, PMID 30188584.
Mishra B, Padaliya R, Patel RR. Exemestane encapsulated vitamin E-TPGS–polymeric nanoparticles: preparation, optimization, characterization, and in vitro cytotoxicity assessment. Artif Cells Nanomed Biotechnol. 2017;45(3):522-34. doi: 10.3109/21691401.2016.1163714, PMID 27017970.
Singh A, Neupane YR, Mangla B, Kohli K. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies. J Pharm Sci. 2019;108(10):3382-95. doi: 10.1016/j.xphs.2019.06.003. PMID 31201904.
Kumar A, Sawant K. Encapsulation of exemestane in polycaprolactone nanoparticles: optimization, characterization, and release kinetics. Cancer Nanotechnol. 2013;4(4-5):57-71. doi: 10.1007/s12645-013-0037-4, PMID 26069501.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Preeti Mane, Dr. Balaji Wakure, Dr. Pravin Wakte
This work is licensed under a Creative Commons Attribution 4.0 International License.
